| Identification | Back Directory | [Name]
PFK-158 | [CAS]
1462249-75-7 | [Synonyms]
PFK-158
PFK-158;PFK 158
PFK-158 free base
PFK-158, ACT-PFK-158
(2E)-1-(4-Pyridinyl)-3-[7-(trifluoromethyl)-2-quinolinyl]-2-propen-1-one
2-Propen-1-one, 1-(4-pyridinyl)-3-[7-(trifluoromethyl)-2-quinolinyl]-, (2E)- | [Molecular Formula]
C18H11F3N2O | [MOL File]
1462249-75-7.mol | [Molecular Weight]
328.29 |
| Chemical Properties | Back Directory | [Boiling point ]
466.3±45.0 °C(Predicted) | [density ]
1.346±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:14.0(Max Conc. mg/mL);42.6(Max Conc. mM) | [form ]
A crystalline solid | [pka]
2.46±0.10(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Description]
PFK158 is an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3; IC50 = 137 nM for human recombinant PFKFB3). It inhibits PFKFB3 and glycolysis in Jurkat cells (IC50s = 1.6 and 0.847 μM, respectively). PFK158 inhibits the growth of leukemia cells in vitro (IC50 = 0.33 μM for Jurkat cells) and reduces tumor volume in CT-26 murine colon carcinoma syngeneic model and a BxPC-3 pancreatic cancer mouse xenograft model. PFK158 also enhances activity of the anti-CTLA-4 antibody in the B16/F10 mouse model of melanoma. | [Uses]
PFK-158 is a potent and selective PFKFB3 inhibitor with an IC50 value 137 nM. PFK-158 reduces glucose uptake, ATP production, lactate release, and induces apoptosis and autophagy in cancer cells. PFK-158 has broad anti-tumor activity. PFK-158 can also enhance Colistin's resistance to bacteria[1][2][3]. | [in vivo]
PFK-158 (15 mg/kg; intraperitoneal injection; once a week; for 4 weeks; female athymic nude mice) plus CBPt (51 mg/kg) treatment leads to significantly enhanced antitumor activity in a gynecologic cancer mouse model[1]. | Animal Model: | Female athymic nude mice (nu/nu) (5-6 weeks old) injected with HeyA8MDR cells[1] | | Dosage: | 15 mg/kg | | Administration: | Intraperitoneal injection; once a week; for 4 weeks | | Result: | A marked reduction of tumor growth was observed in the combination treatment.
|
| [References]
[1] Mondal S, et al. Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers. Int J Cancer. 2019 Jan 1;144(1):178-189. DOI:10.1002/ijc.31868
[2] Zhang Y, et al. Synergistic Effect of Colistin Combined with PFK-158 against Colistin-Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00271-19. DOI:10.1128/AAC.00271-19
[3] Pooran Chand, et al. Pfkfb3 inhibitor and methods of use as an anti-cancer therapeutic. WO2013148228A1. |
|
|